ADX-001 / Adaxion Therapeutics - LARVOL DELTA

Proof-of-concept Study of New Imaging Diagnostic in Patients With Suspected Alzheimer's Disease (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: Alzeca Biosciences, Inc.

First-in-human • New P1 trial • Alzheimer's Disease • CNS Disorders

Proof-of-concept Study of New Imaging Diagnostic in Patients With Suspected Alzheimer's Disease (clinicaltrials.gov) - P1 | N=16 | Terminated | Sponsor: Alzeca Biosciences, Inc. | Recruiting ➔ Terminated; A temperature excursion occurred at the drug supplier's storage facility, which led to the loss of a significant portion of the IMP stock. Consequently, there is not enough IMP available to support continued recruitment

First-in-human • Trial termination • Alzheimer's Disease • CNS Disorders

Proof-of-concept Study of New Imaging Diagnostic in Patients With Suspected Alzheimer's Disease (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: Alzeca Biosciences, Inc. | Initiation date: Jul 2022 ➔ Nov 2022

First-in-human • Trial initiation date • Alzheimer's Disease • CNS Disorders

Proof-of-concept Study of New Imaging Diagnostic in Patients With Suspected Alzheimer's Disease (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: Alzeca Biosciences, Inc. | Trial completion date: Jun 2024 ➔ Jan 2025 | Trial primary completion date: Jun 2024 ➔ Jan 2025

First-in-human • Trial completion date • Trial primary completion date • Alzheimer's Disease • CNS Disorders